Blue toe syndrome, severe haemophilia A and emicizumab

Article Hematology

Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY)

Victor Jimenez-Yuste et al.

Summary: This study confirms the safety profile of emicizumab prophylaxis in patients with hemophilia A and FVIII inhibitors, with the majority of participants experiencing no treated bleeds.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY)

Victor Jimenez-Yuste et al.

Summary: The study confirmed the safety profile of emicizumab prophylaxis in people with hemophilia A with FVIII inhibitors, with no new safety signals observed, and the majority of participants had zero treated bleeds.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan et al.

Summary: Long-term data from pooled studies show that prophylaxis with emicizumab maintains low bleed rates in persons with hemophilia A of all ages, with good tolerability and no new safety concerns.

BLOOD (2021)

Add to Collection

Review Biochemistry & Molecular Biology